vs
Affirm Holdings, Inc.（AFRM）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Affirm Holdings, Inc.の直近四半期売上が大きい（$401.4M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.4倍）。Affirm Holdings, Inc.の純利益率が高く（32.3% vs 16.5%、差は15.8%）。Affirm Holdings, Inc.の前年同期比売上増加率が高い（32.5% vs -2.4%）。Affirm Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$118.0M vs $75.3M）。過去8四半期でAffirm Holdings, Inc.の売上複合成長率が高い（43.5% vs 1.2%）
アファーム・ホールディングスは米国の金融テクノロジー企業で、購入時ローンや後払い決済サービス（BNPL）を提供しています。PayPal共同創業者のマックス・レフチンが2012年に設立した米国最大のBNPL事業者で、2025年現在利用者数は約2600万人、年間決済処理額は370億米ドルに上ります。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
AFRM vs PBH — 直接比較
損益計算書 — Q2 FY2026 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $401.4M | $283.4M |
| 純利益 | $129.6M | $46.7M |
| 粗利率 | — | 55.5% |
| 営業利益率 | 29.3% | 29.1% |
| 純利益率 | 32.3% | 16.5% |
| 売上前年比 | 32.5% | -2.4% |
| 純利益前年比 | 61.3% | -23.5% |
| EPS（希薄化後） | $0.37 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $401.4M | $283.4M | ||
| Q3 25 | $320.5M | $274.1M | ||
| Q2 25 | $306.6M | $249.5M | ||
| Q1 25 | $272.5M | $296.5M | ||
| Q4 24 | $303.0M | $290.3M | ||
| Q3 24 | $231.8M | $283.8M | ||
| Q2 24 | $224.0M | $267.1M | ||
| Q1 24 | $195.0M | $277.0M |
| Q4 25 | $129.6M | $46.7M | ||
| Q3 25 | $80.7M | $42.2M | ||
| Q2 25 | $69.2M | $47.5M | ||
| Q1 25 | $2.8M | $50.1M | ||
| Q4 24 | $80.4M | $61.0M | ||
| Q3 24 | $-100.2M | $54.4M | ||
| Q2 24 | $-45.1M | $49.1M | ||
| Q1 24 | $-133.9M | $49.5M |
| Q4 25 | — | 55.5% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | — | 54.7% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | 29.3% | 29.1% | ||
| Q3 25 | 19.9% | 29.1% | ||
| Q2 25 | 18.9% | 28.8% | ||
| Q1 25 | -3.1% | 29.8% | ||
| Q4 24 | -1.4% | 31.7% | ||
| Q3 24 | -57.2% | 29.7% | ||
| Q2 24 | -32.8% | 27.0% | ||
| Q1 24 | -82.5% | 29.7% |
| Q4 25 | 32.3% | 16.5% | ||
| Q3 25 | 25.2% | 15.4% | ||
| Q2 25 | 22.6% | 19.0% | ||
| Q1 25 | 1.0% | 16.9% | ||
| Q4 24 | 26.5% | 21.0% | ||
| Q3 24 | -43.2% | 19.2% | ||
| Q2 24 | -20.2% | 18.4% | ||
| Q1 24 | -68.7% | 17.9% |
| Q4 25 | $0.37 | $0.97 | ||
| Q3 25 | $0.23 | $0.86 | ||
| Q2 25 | $0.22 | $0.95 | ||
| Q1 25 | $0.01 | $1.00 | ||
| Q4 24 | $0.23 | $1.22 | ||
| Q3 24 | $-0.31 | $1.09 | ||
| Q2 24 | $-0.13 | $0.98 | ||
| Q1 24 | $-0.43 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $1.5B | $62.4M |
| 総負債低いほど良い | $9.0B | $1.0B |
| 株主資本純資産 | $3.5B | $1.8B |
| 総資産 | $13.0B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 2.54× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $1.5B | $62.4M | ||
| Q3 25 | $1.4B | $119.1M | ||
| Q2 25 | $1.4B | $139.5M | ||
| Q1 25 | $1.4B | $97.9M | ||
| Q4 24 | $1.2B | $50.9M | ||
| Q3 24 | $1.0B | $51.5M | ||
| Q2 24 | $1.0B | $34.3M | ||
| Q1 24 | $1.3B | $46.5M |
| Q4 25 | $9.0B | $1.0B | ||
| Q3 25 | $7.7B | $993.1M | ||
| Q2 25 | $7.6B | $992.7M | ||
| Q1 25 | $7.1B | $992.4M | ||
| Q4 24 | $7.3B | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | $1.8B | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $3.5B | $1.8B | ||
| Q3 25 | $3.3B | $1.8B | ||
| Q2 25 | $3.1B | $1.9B | ||
| Q1 25 | $2.9B | $1.8B | ||
| Q4 24 | $2.8B | $1.8B | ||
| Q3 24 | $2.8B | $1.7B | ||
| Q2 24 | $2.7B | $1.7B | ||
| Q1 24 | $2.6B | $1.7B |
| Q4 25 | $13.0B | $3.5B | ||
| Q3 25 | $11.5B | $3.4B | ||
| Q2 25 | $11.2B | $3.4B | ||
| Q1 25 | $10.4B | $3.4B | ||
| Q4 24 | $10.5B | $3.3B | ||
| Q3 24 | $10.1B | $3.3B | ||
| Q2 24 | $9.5B | $3.3B | ||
| Q1 24 | $9.2B | $3.3B |
| Q4 25 | 2.54× | 0.56× | ||
| Q3 25 | 2.35× | 0.54× | ||
| Q2 25 | 2.48× | 0.54× | ||
| Q1 25 | 2.49× | 0.54× | ||
| Q4 24 | 2.62× | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | 0.67× | 0.65× | ||
| Q1 24 | — | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $173.7M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $118.0M | $75.3M |
| FCFマージンFCF / 売上 | 29.4% | 26.6% |
| 設備投資強度設備投資 / 売上 | 13.9% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.34× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | $619.1M | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $173.7M | $78.3M | ||
| Q3 25 | $374.6M | $57.5M | ||
| Q2 25 | $74.6M | $79.0M | ||
| Q1 25 | $210.4M | $61.8M | ||
| Q4 24 | $312.0M | $65.1M | ||
| Q3 24 | $196.9M | $69.8M | ||
| Q2 24 | $68.8M | $54.8M | ||
| Q1 24 | $208.2M | $66.9M |
| Q4 25 | $118.0M | $75.3M | ||
| Q3 25 | $320.2M | $55.4M | ||
| Q2 25 | $23.5M | $78.2M | ||
| Q1 25 | $157.4M | $58.4M | ||
| Q4 24 | $268.1M | $63.5M | ||
| Q3 24 | $152.7M | $67.8M | ||
| Q2 24 | $30.5M | $53.6M | ||
| Q1 24 | $161.7M | $63.8M |
| Q4 25 | 29.4% | 26.6% | ||
| Q3 25 | 99.9% | 20.2% | ||
| Q2 25 | 7.7% | 31.3% | ||
| Q1 25 | 57.7% | 19.7% | ||
| Q4 24 | 88.5% | 21.9% | ||
| Q3 24 | 65.9% | 23.9% | ||
| Q2 24 | 13.6% | 20.1% | ||
| Q1 24 | 82.9% | 23.0% |
| Q4 25 | 13.9% | 1.1% | ||
| Q3 25 | 17.0% | 0.8% | ||
| Q2 25 | 16.7% | 0.3% | ||
| Q1 25 | 19.5% | 1.2% | ||
| Q4 24 | 14.5% | 0.5% | ||
| Q3 24 | 19.0% | 0.7% | ||
| Q2 24 | 17.1% | 0.4% | ||
| Q1 24 | 23.8% | 1.1% |
| Q4 25 | 1.34× | 1.68× | ||
| Q3 25 | 4.64× | 1.36× | ||
| Q2 25 | 1.08× | 1.66× | ||
| Q1 25 | 75.03× | 1.23× | ||
| Q4 24 | 3.88× | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | — | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AFRM
| Merchant Network | $328.4M | 82% |
| Virtual Card Network | $73.0M | 18% |
| Commercial Agreement Amazon | $1.9M | 0% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
